Urinary 6‐hydroxymelatonin sulfate excretion in intellectually disabled subjects with sleep disorders and multiple medications: Validation of measurements in urine extracted from diapers

References

• Perreau‐Lenz S., Pévet P., Buijs R. M., Kalsbeek A. The biological clock: the bodyguard of temporal homeostasis. Chronobiol Int 2004; 21: 1–25
   PubMed Web of Science ®Google Scholar
• Kauymov L., Brown G., Jindal R., Buttoo K., Shapiro C. M. A randomized, double‐blind, placebo‐controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med 2001; 63: 40–8
   PubMedGoogle Scholar
• Hack L. M., Lockley S. W., Arendt J., Skene D. J. The effects of low‐dose 0.5‐mg melatonin on the free‐running circadian rhythms of blind subjects. J Biol Rhythms 2003; 18: 420–9
   PubMed Web of Science ®Google Scholar
• Lewy A. J., Emens J., Sack R. L., Hasler B. P., Bernert R. A. Zeitgeber hierarchy in humans: resetting the circadian phase position of blind people using melatonin. Chronobiol Int 2003; 20: 837–52
   PubMed Web of Science ®Google Scholar
• Monti J. M., Alvarino F., Cardinali D., Savio I., Pintos A. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 1999; 28: 85–98
   PubMed Web of Science ®Google Scholar
• Niederhofer H., Staffen W., Mair A., Pittschieler K. Brief report: Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Dev Disord 2003; 33: 469–72
   PubMedGoogle Scholar
• Ellis C. M., Lemmens G., Parkes J. D. Melatonin and insomnia. J Sleep Res 1996; 5: 61–5
   PubMed Web of Science ®Google Scholar
• Singer C., Tractenberg R. E., Kaye J., Schafer K., Gamst A., Grundman M. A multicenter, placebo‐controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 839–901
   PubMedGoogle Scholar
• Zhdanova I. V., Tucci V. Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol 2003; 5: 225–9
   PubMedGoogle Scholar
• Leger D., Laudon M., Zisapel N. Nocturnal 6‐sufatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116: 91–5
   PubMed Web of Science ®Google Scholar
• Arendt J., Bojkowski C., Franey C., Wright J., Marks V. Immunoassay of 6‐hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24‐hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166–73
   PubMed Web of Science ®Google Scholar
• Markey S. P., Higa S., Shih M., Danforth D. N., Tamarkin L. The correlation between human plasma melatonin levels and urinary 6‐hydroxymelatonin excretion. Clin Chim Acta 1985; 150: 221–5
   PubMed Web of Science ®Google Scholar
• Nowak R., McMillen I. C., Redman J., Short R. V. The correlation between serum and salivary melatonin concentrations and urinary 6‐hydroxymelatonin sulphate excretion rates: two non‐invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol 1987; 27: 445–52
   PubMed Web of Science ®Google Scholar
• Bojkowski C. J., Arendt J., Shih M. C., Markey S. P. Melatonin secretion in humans assessed by measuring its metabolite, 6‐sulfatoxymelatonin. Clin Chem 1987; 33: 1343–8
   PubMed Web of Science ®Google Scholar
• Bojkowski C. J., Arendt J. Annual changes in 6‐sulphatoxymelatonin excretion in man. Acta Endocrinol (Copenh) 1988; 117: 470–6
   PubMedGoogle Scholar
• Deacon S. J., Arendt J. Phase‐shifts in melatonin, 6‐sulphatoxymelatonin and alertness rhythms after treatment with moderately bright light at night. Clin Endocrinol 1994; 40: 413–20
   PubMed Web of Science ®Google Scholar
• Graham C., Cook M. R., Kavet R., Sastre A., Smith D. K. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 1998; 24: 230–8
   Web of Science ®Google Scholar
• Cook M. R., Graham C., Kavet R., Stevens R. G., Davis S., Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res 2000; 28: 41–7
   PubMed Web of Science ®Google Scholar
• Crasson M., Kjiri S., Colin A., Kjiri K., L'Hermite‐Baleriaux M., Ansseau M. Serum melatonin and urinary 6‐sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004; 29: 1–12
   PubMed Web of Science ®Google Scholar
• Manz B., Alexander H., Wagner B., Pollow K. 24 hr pattern of serum melatonin in patients with anorexia nervosa determined by a novel 125I‐radioimmunoassay without extraction. Neuroendocrinology: new frontiers, D Gupta, H. A Wollman, M. B Ranke. Brain Research Promotion, London, Tübingen 1990; 255–64
   Google Scholar
• Aldhous M. E., Arendt J. Radioimmunoassay for 6‐sulphatoxymelatonin in urine using an iodinated tracer. Ann Clin Biochem 1988; 25: 298–303
   PubMed Web of Science ®Google Scholar
• Griefahn B., Remer T., Blaszkewicz M., Brode P. Long‐term stability of 6‐hydroxymelatonin sulfate in 24‐h urine samples stored at −20 degrees C. Endocrine 2001; 15: 199–202
   PubMed Web of Science ®Google Scholar
• Sadeh A. Sleep and melatonin in infants: a preliminary study. Sleep 1997; 20: 185–91
   PubMed Web of Science ®Google Scholar
• Sivan Y., Laudon M., Kuint J., Zisapel N. Low melatonin production in infants with a life‐threatening event. Dev Med Child Neurol 2000; 42: 487–91
   PubMedGoogle Scholar
• Hajak G., Rodenbeck A., Staedt J., Bandelow B., Huether G., Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res 1995; 19: 116–22
   PubMed Web of Science ®Google Scholar
• Lushington K., Dawson D., Kennaway D. J., Lack L. The relationship between 6‐sulphatoxymelatonin and polysomnographic sleep in good sleeping controls and wake maintenance insomniacs, aged 55–80 years. J Sleep Res 1999; 8: 57–64
   PubMedGoogle Scholar
• Baskett J. J., Wood P. C., Broad J. B., Duncan J. R., English J., Arendt J. Melatonin in older people with age‐related sleep‐maintenance problems: a comparison with age matched normal sleepers. Sleep 2001; 24: 418–24
   PubMed Web of Science ®Google Scholar
• Monk T. H., Buysse D. J., Billy B. D., Kennedy K. S., Kupfer D. J. The effects on human sleep and circadian rhythms of 17 days of continuous bedrest in the absence of daylight. Sleep 1997; 20: 858–64
   PubMed Web of Science ®Google Scholar
• Molina‐Carballo A., Acuña‐Castroviejo D., Rodriguez‐Cabezas T., Muños‐Hoyos A. Effects of febrile and epileptic convulsions on daily variations in plasma melatonin concentrations in children. J Pineal Res 1994; 16: 1–9
   PubMed Web of Science ®Google Scholar
• Schapel G. J., Beran R. G., Kennaway D. L., McLoughney J., Matthews C. D. Melatonin response in active epilepsy. Epilepsia 1995; 36: 75–8
   PubMed Web of Science ®Google Scholar
• Bazil C. W., Short D., Crispin D., Zheng W. Patients with intractable epilepsy have low melatonin, which increases following seizures. Neurology 2000; 55: 1746–8
   PubMed Web of Science ®Google Scholar
• McIntyre I. M., Burrows G. D., Norman T. R. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatry 1988; 24: 108–12
   PubMed Web of Science ®Google Scholar
• Copinschi G., Van Onderbergen A., L'Hermite‐Balériaux M. L., Szyper M., Caufriez A., Bosson D. Effects of the short‐acting benzodiazepine triazolam, taken at bedtime, on circadian and sleep‐related hormonal profiles in normal men. Sleep 1990; 13: 232–44
   PubMedGoogle Scholar
• Allen N. H. P., Smythe P. J., Martin N., Plaskett L., Osola K., Childs P. The effect of temazepam on melatonin secretion and light sensitivity. J Psychopharmacol 1994; 8: 94–7
   PubMedGoogle Scholar
• Monteleone P., Tortorella A., Borriello R., Natale M., Cassandro P., Maj M. Suppression of nocturnal plasma melatonin levels by evening administration of sodium valproate in healthy humans. Biol Psychiatry 1997; 41: 336–41
   PubMedGoogle Scholar
• Kopin I. J., Pare C. M. B., Axelrod J., Weissbach H. 6‐Hydroxylation, the major metabolic pathway for melatonin. Biochim Biophys Acta 1960; 40: 377–8
   PubMed Web of Science ®Google Scholar
• Kopin I. J., Pare C. M. B., Axelrod J., Weissbach H. The fate of melatonin in animals. J Biol Chem 1961; 236: 3072–5
   PubMed Web of Science ®Google Scholar
• Kveder S., McIsaac W. M. The metabolism of melatonin (N‐acetyl‐5‐methoxytryptamine) and 5‐methoxytryptamine. J Biol Chem 1961; 236: 3214–20
   PubMedGoogle Scholar
• Jones R. L., McGeer P. L., Greiner A. C. Metabolism of exogenous melatonin in schizophrenic and non‐schizophrenic volunteers. Clin Chim Acta 1969; 26: 281–5
   PubMed Web of Science ®Google Scholar
• Leone R. M., Silman R. E. Melatonin can be differentially metabolized in the rat to produce N‐acetylserotonin in addition to 6‐hydroxy‐melatonin. Endocrinology 1984; 114: 1825–32
   PubMedGoogle Scholar
• Young I. M., Leone R. M., Francis P., Stovell P., Silman R. E. Melatonin is metabolized to N‐acetyl serotonin and 6‐hydroxymelatonin in man. J Clin Endocrinol Metab 1985; 60: 114–9
   PubMed Web of Science ®Google Scholar
• Di W‐L., Djahanbakhch O., Kadva A., Street C., Silman R. The pineal and extra‐pineal origins of 5‐sulphatoxy N‐acetyl‐serotonin in humans. J Pineal Res 1999; 26: 221–6
   PubMedGoogle Scholar
• Hardeland R., Reiter R. J., Poeggeler B., Tan D. X. The significance of the metabolism of the neurohormone melatonin antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993; 17: 347–57
   PubMed Web of Science ®Google Scholar
• Tan D. X., Reiter R. J., Manchester L. C., Yan M. T., El‐Sawi M., Sainz RM M JC. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181–97
   PubMedGoogle Scholar
• Yeleswaram K., Vachharajani N., Santone K. Involvement of cytochrome P‐450 isoenzymes in melatonin metabolism and clinical implications. J Pineal Res 1999; 26: 190–1
   PubMed Web of Science ®Google Scholar
• Skene D. J., Papagiannidou E., Hashemi E., Snelling J., Lewis D. F. W., Fernandez M. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res 2001; 31: 333–42
   PubMed Web of Science ®Google Scholar
• Facciolá G., Hidestrand M., von Bahr C., Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001; 56: 881–8
   PubMed Web of Science ®Google Scholar
• Ursing C., Wikner J., Brismar K., Röjdmark S. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2. J Endocrinol Invest 2003; 26: 403–6
   PubMed Web of Science ®Google Scholar
• Skene D. J., Bojkowski C. J., Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 1994; 37: 181–6
   PubMedGoogle Scholar
• Härtter S., Wang X., Weigmann H., Friedberg T., Arand M., Oesch F. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21: 167–74
   PubMed Web of Science ®Google Scholar
• Singer S. S., Hagedorn J. E., Smith D. M., Williams J. L. The enzymatic basis for the rat liver 6‐hydroxymelatonin sulfotransferase activity. J Pineal Res 1995; 18: 49–55
   PubMedGoogle Scholar
• Honma W., Kamiyama Y., Yoshinari K., Sasano H., Shimada M., Nagata K. Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos 2001; 29: 274–81
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Nakano T., Ose A., Horie T. Differential selectivity in carbamazepine‐induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch Toxicol 2001; 75: 538–43
   PubMed Web of Science ®Google Scholar
• Daniel W. A., Syrek M., Rylko Z., Kot M. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol J Pharmacol 2001; 53: 615–21
   PubMedGoogle Scholar
• Granfors M. T., Backman J. T., Laitila J., Neuvonen P. J. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol 2003; 57: 349–53
   Google Scholar
• Han X. M., Ouyang D. S., Chen X. P., Shu Y., Jiang C. H., Tan Z. R. Inducibility of CYP1A2 by omeprazolein vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002; 54: 540–3
   PubMed Web of Science ®Google Scholar
• Ono S., Hatanaka T., Miyazawa S., Tsutsui M., Aoyama T., Gonzalez F. J., S. T. Human liver microsomal diazepam metabolism using cDNA‐expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26: 1155–66
   PubMed Web of Science ®Google Scholar
• Giraud C., Tran A., Rey E., Vincent J., Treluyer J. M., Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004; 32: 1279–86
   PubMed Web of Science ®Google Scholar
• Meyer U. A. Metabolic interactions of the proton‐pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastoenterol Hepatol 1996; 8 Suppl 1: S21–S5
   Google Scholar
• Yu B‐N., Chen G‐L., He N., Ouyang D‐S., Chen X‐P., Liu Z‐Q. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003; 31: 1255–9
   PubMed Web of Science ®Google Scholar
• Raucy J. L., Mueller L., Duan K., Allen S. W., Strom S., Lasker J. M. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002; 302: 475–82
   PubMed Web of Science ®Google Scholar
• Lakehal F., Wurden C. J., Kalhorn T. F., Levy R. H. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res 2002; 52: 79–83
   PubMed Web of Science ®Google Scholar
• Wen X., Wang J. S., Kivistö K. T., Neuvonen P. J., Backman J. T. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52: 547–53
   PubMed Web of Science ®Google Scholar
• Beedham C., Smith J. A., Steele D. L., Wright P. A. Chlorpromazine inhibition of melatonin metabolism by normal and induced rat liver microsomes. Eur J Drug Metab Pharmacokin 1987; 12: 299–302
   PubMedGoogle Scholar
• Wood S. G., John B. A., Chasseaud L. F., Yeh J., Chung M. The metabolism and pharmacokinetics of 14C‐cetirizine in humans. Ann Allergy 1987; 59: 31–4
   PubMedGoogle Scholar